Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.

Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan.
Epidemiologic Reviews (Impact Factor: 7.33). 02/2006; 28:126-35. DOI: 10.1093/epirev/mxj010
Source: PubMed

ABSTRACT The national hepatitis B vaccination program in Taiwan is considered one of the most successful and effective public health programs to control chronic hepatitis B infection in the past 20 years. This review illustrates how to implement a successful hepatitis B vaccination program based on Taiwan's experience. Several important controlled randomized clinical trials on hepatitis B immunoglobulin and vaccine in Taiwan demonstrated an 80-90% protective effect among infants of mothers who were positive for either hepatitis B envelope antigen or hepatitis B surface antigen. A series of prevalence surveys on children born before and after the national vaccination program began disclosed a steady decrease in seroprevalence of hepatitis B surface antigen in Taiwan, with 78-87% effectiveness after the national vaccination program was launched. Studies on the secular trend of liver disease risk also documented a 68% decline in mortality from fulminant hepatitis in infants and a 75% decrease in the incidence of hepatocellular carcinoma in children 6-9 years of age after the national vaccination program began. In conclusion, since 1984, the national hepatitis B vaccination program has been successful in preventing acute and chronic liver diseases in Taiwan.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Safe blood transfusion where hepatitis is endemic In South-East Asia the prevalence of hepatitis B and C virus infections is high. Accurate – yet low-cost – screening of blood donors is crucial to avoid transfusion-transmitted disease. On (DATE) Le Viet will defend his thesis “Safe Blood Transfusion: Screening for Hepatitis B and Hepatitis C Virus Infections in Potential Blood Donors in Rural Southeast Asia” for the PhD degree at the Faculty of Health Sciences at UiT. The first aim of the thesis is to identify the accuracy of rapid tests for detection of acute hepatitis B, occult hepatitis B, and hepatitis C virus infections in potential blood donor in rural Vietnam and Cambodia. The second aim is to estimate prevalence of these infections among potential rural blood donors in Vietnam, and to examine the accuracy of enzyme immunoassay (EIA) technique in blood donor screening. The final goal is to estimate the risk of transfusion-transmitted hepatitis B in Vietnamese blood donors based on the available prevalence data and estimated prevalence of occult hepatitis B infection. 2,400 blood samples from potential voluntary rural blood donors in a multicentre cross-sectional study in Cambodia and Vietnam were analysed with rapid and EIA tests for detection of HBsAg, anti-HBc and anti-HCV at local laboratories. 640 randomly selected blood samples were blindly validated in a Norwegian accredited micro-laboratory by a chemiluminescent micro particle immunoassay technique (CMIA). Rapid test for donor screening of hepatitis proved to have far lover accuracy than claimed by the manufacturer; especially the false-negative rate was unacceptably high. The study revealed that hepatitis B infection is endemic in rural Vietnam and almost half of Vietnamese population is or has been infected with hepatitis B while hepatitis C infection is rare. The results indicate that the EIA performance in blood donor screening in Vietnam may be sub-optimal. The major risk factors for post- transfusion are HBsAg false-negative results and potential occult hepatitis B infections. Increased test sensitivity and locally validated HBsAg assays are recommended.
    11/2014, Degree: Philosophy Doctor (PhD), Supervisor: Hans Husums, Anne Husebekk, Eystein Skjerve
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Coxiella burnetii is an obligate bacterial pathogen that causes Q fever. Cytomegalovirus (CMV) commonly exists as a latent infection in healthy people. Co-infection with both pathogens is rare.Case presentationWe report an immunocompetent 53-year-old male farmer who presented with fulminant hepatic failure and acute renal failure. Empiric antibiotic treatment with intravenous penicillin G and levofloxacin were given, but hepatic and renal functions continued to deteriorate. A subsequent test of serum immunoglobulin M was positive for CMV, and administration of gancyclovir led to gradual recovery. A diagnosis of acute Q fever was confirmed by indirect immunofluorescence assay (IFA) on paired serum samples to demonstrate a significant rise in antibody titers. Antibiotic treatment was adjusted accordingly.ConclusionCMV co-infection should be considered in patients with acute Q fever when they do not respond to standard antimicrobial agents.
    BMC Infectious Diseases 12/2014; 14(1):651. · 2.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We aim to determine the incidence of malignancy after liver transplantation (LT) compared to general population.The records of patients who received LTs at our center from October 1989 and November 2012 were retrospectively reviewed. The standardized incidence ratio (SIR) of cancer in the patients was compared to general population using the data from the Taiwan Cancer Registry. Survival was estimated using the Kaplan-Meier method.A total of 444 patients were included. Malignancy was found in 46 (28 de novo and 19 recurrent malignancies) patients (10.4%) with the median follow up of 4.2 ± 4.2 years. The median time of cancer occurrence after transplant was 1.2 ± 1.9 years (range, 0.2-9.1 years). Post-transplant lymphoproliferative disorder was the most frequent de novo malignancy (57.1% [16/28]). The cumulative incidence rates of all malignancies were 5.1%, 10.4%, 12.8%, 15.8%, and 15.8% at 1, 3, 5, 10, and 15 years, respectively. The cumulative incidence rates of de novo malignancies were 3.4%, 5.97%, 7.7%, 10.9%, and 10.9 % at 1, 3, 5, 10, and 15 years. Compared to general population, transplant recipients had significantly higher incidence of all de novo cancers (SIR: 3.26, 95% confidence interval [CI]: 2.17-4.72), hematologic (SIR: 58.4; 95% CI, 33.3-94.8), and bladder (SIR: 10.2, 95% CI: 1.1-36.7) cancers. The estimated mean survivals after transplantation in cancer-free, de novo cancer, and recurrent cancer patients were 17.7 ± 0.5, 11.3 ± 1.2, and 3.6 ± 0.6 years, respectively.There is a significantly increased risk of malignancies after LT in the Taiwanese population.
    Medicine 12/2014; 93(28):e310. · 4.87 Impact Factor